MYO7A and Hearing impairment: (2025) represents a significant milestone in this context, successfully expanding this therapeutic repertoire by treating myosin VIIa (MYO7A)‐related hearing impairment in the Shaker‐1 (Myo7ash1/sh1) mouse model.